Drugs / P-PSMA-101 CAR-T cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04249947 | Feb 2020 → Sep 2024 | adenoid cystic carcinoma, castration-resistant prostate carcinoma, mucoepidermoid carcinoma, salivary duct carcinoma +1 | Poseida Therapeutics, Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | P-PSMA-101 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04249947 ↗ |
| Modality | Cell therapy | “autologous chimeric antigen receptor (CAR) T-cell therapy” NCT04249947 ↗ |
| Route | Intravenous | “given in a single intravenous infusion of CAR-T cells” NCT04249947 ↗ |